Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
BMJ Supportive & Palliative Care|August 14, 2021
Cardiorespiratory fitness in breast cancer survivors: a randomised controlled trial of home-based smartphone supported high intensity interval trainingEisuke Ochi, Katsunori Tsuji, Tomomi Narisawa, et al.
Asian Journal of Surgery|February 2, 2023
Clinical significance of tumor cell seeding associated with needle biopsy in patients with breast cancerHaruhi Maseki, Kenjiro Jimbo, Chikashi Watase, et al.
Molecular and Clinical Oncology|January 24, 2022
Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapyChikako Sekine, Nachiko Uchiyama, Chikashi Watase, et al.
International Journal of Surgery Case Reports|March 21, 2020
Locally advanced triple negative breast cancer arising from fibroadenoma with complete response to neoadjuvant chemotherapy: A case reportSho Shiino, Masayuki Yoshida, Momoko Tokura, et al.
Scientific Reports|November 11, 2023
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancerShohei Shikata, Takeshi Murata, Masayuki Yoshida, et al.
Breast Cancer (Tokyo, Japan)|August 23, 2023
Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancerTakeshi Murata, Masayuki Yoshida, Sho Shiino, et al.
JMA Journal|November 9, 2023
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health ServicesShin Takayama, Takayuki Kinoshita, Sho Shiino, et al.
The Lancet. Oncology|January 2, 2021
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trialMasakazu Toi, Shigeru Imoto, Takanori Ishida, et al.
Pageof 3